Evenity vs Forteo for Severe Osteoporosis with Glucocorticoid-Induced Osteoporosis
For patients with severe osteoporosis and glucocorticoid-induced osteoporosis, teriparatide (Forteo) is preferred over romosozumab (Evenity) due to its established efficacy in this specific population and better safety profile.
Treatment Recommendation Algorithm
First-line Treatment:
- Teriparatide (Forteo)
- Recommended for patients with severe osteoporosis and glucocorticoid-induced osteoporosis
- Dosage: 20 μg daily subcutaneous injection
- Duration: Up to 2 years (maximum FDA-approved duration)
- Requires calcium intake of 1,000-1,200 mg/day and vitamin D 600-800 IU/day
Second-line Options (if teriparatide is not appropriate):
- Oral bisphosphonates
- IV bisphosphonates
- Denosumab
Not Recommended:
- Romosozumab (Evenity) - conditionally recommended against in moderate fracture risk patients due to risks of myocardial infarction, stroke, or death 1
Evidence Supporting Teriparatide for GIOP
The 2023 American College of Rheumatology guidelines for glucocorticoid-induced osteoporosis (GIOP) conditionally recommend anabolic agents like teriparatide over anti-resorptive agents for patients with very high fracture risk 2, 1. This recommendation is based on evidence showing:
- Teriparatide increases lumbar and hip BMD and decreases vertebral fractures more effectively than alendronate at 36 months in GIOP patients 2
- The anabolic (bone-forming) mechanism of teriparatide is particularly beneficial for severe osteoporosis cases where rapid bone formation is needed 1
For patients receiving frequent or chronic prednisone, teriparatide has demonstrated superior efficacy compared to bisphosphonates at increasing bone mineral density 1.
Limitations of Romosozumab in This Context
While romosozumab is a potent anabolic agent, the 2023 ACR guidelines conditionally recommend against using it in moderate fracture risk patients except in those intolerant of other agents 2, 1. This is due to:
- Increased risks of myocardial infarction, stroke, or death
- Limited safety data specifically in GIOP patients
- Less established track record compared to teriparatide for GIOP
Monitoring and Follow-up
- Perform BMD testing every 1-2 years with vertebral fracture assessment (VFA) or spinal X-rays 2
- Monitor serum calcium after 1 month of treatment 3
- Mild hypercalcemia can be managed by reducing dietary calcium supplements or adjusting teriparatide dosing frequency 3
Important Considerations
- Duration limitation: Teriparatide should not be used for more than 2 years due to the potential risk of osteosarcoma (based on rat studies) 3
- Sequential therapy: After completing teriparatide treatment, transition to an antiresorptive agent to maintain bone gains 1
- Avoid concurrent therapy: Combining teriparatide with bisphosphonates may blunt the anabolic response 1, 3
- Contraindications: Teriparatide should not be used in patients with Paget's disease, unexplained elevations of alkaline phosphatase, prior radiation therapy involving the skeleton, bone metastases, or history of skeletal malignancies
Lifestyle and Supplementation
In addition to pharmacological treatment:
- Optimize calcium intake (1,000-1,200 mg/day) and vitamin D (600-800 IU/day)
- Implement fall prevention strategies
- Encourage weight-bearing and resistance exercises as tolerated
- Recommend smoking cessation and limiting alcohol intake to 1-2 servings per day 1
By following this approach, patients with severe osteoporosis and glucocorticoid-induced osteoporosis can receive the most effective treatment to reduce fracture risk and improve bone health.